Home » Intravitreal Injectables Market

Intravitreal Injectables Market By Indication (Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusions, Endophthalmitis, Others), By Drug Class (Anti-VEGF, Corticosteroids, Antibiotics, Antivirals, Antifungals) – Growth, Future Prospects, Competitive Analysis, 2018 – 2026

Price: $4999

Published: | Report ID: 7250 | Report Format : PDF

Industry Outlook

The intravitreal injectables market will showcase stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2018 to 2026. According to the statistics provided by the World Health Organization (WHO), approximately 1.3 billion people throughout the globe are suffering from some form of blindness caused majorly by macular degeneration, diabetic retinopathy, ocular vein occlusions, endophthalmitis, and retinitis. Intravitreal injections are preferred over other treatment options for treating disease-associated visual impairment.

Market Synopsis

Macular degeneration market growth is being driven by rising diabetes prevalence and an aging population.

As per the research cited in the Lancet journal, the global prevalence rate of any age-related macular degeneration is 8.69%, with a higher prevalence rate in the Caucasian population followed by mongoloids. The growing geriatric population, smoking, obesity, genetics, diabetes, and other risk factors all contribute to the occurrence of macular degeneration. Diabetic retinopathy is a secondary disease manifestation occurring in elderly people with a previous history of diabetes. Endophthalmitis is growing at a faster rate owing to the rise in air and water pollution and eye trauma.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Excellent biocompatibility and impressive pharmacodynamic properties drive the anti-VEGF drug market.

Anti-VEGF is dominating the drug class segment for intravitreal injections. Drugs like bevacizumab (Avastin), ranibizumab (Lucentis), and others have been used as first-line therapy in patients with neovascular age-related macular degeneration and ocular vein occlusion since their commercialization in 2006. Its inherent features, such as excellent biocompatibility and impressive pharmacodynamic properties, have led to its increased popularity among ophthalmologists worldwide. Corticosteroids are used as an adjuvant medication to treat inflammation caused by eye infections. Antifungal drugs and antibiotics together are prescribed for eye infections such as endophthalmitis and retinitis.

The rising prevalence of eye disorders, combined with an affordable reimbursement scenario, is driving the growth of the intravitreal injectables market.

In the present situation, North America is responsible for 37% of the market share in the regional segment of the intravitreal injectables market. As per the statistics provided by the Centers for Disease Control and Prevention (CDC), approximately 3.3 million Americans aged 40 years and older are blind or suffer from low vision. The rising prevalence of eye disorders, combined with an affordable reimbursement scenario, is driving market growth in North America. Europe accounts for 26% of the market due to the presence of thriving healthcare infrastructure as well as the headquarters of key players such as Novartis AG, Allergan, Inc., Alimera Sciences, F. Hoffman-La Roche Ltd., and others, which drive the market’s growth in Europe. Asia Pacific holds a 20% market share and is keen to capture the regional market in the near future on account of the supportive regulatory environment provided by healthcare agencies and the development of ophthalmic research centers providing optimum eye care.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Report Scope by Segments

The market is segmented by indication, drug class, and geography.

Pharmaceutical giants competing to maintain a stronghold in the intravitreal injectables market are Allergan, Inc., Genetech, Inc., Alimera Sciences, Bristol-Myers Squibb Company, Eyetech, Inc., F. Hoffman-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., ThromboGenics, Inc., and Valeant Pharmaceuticals International, Inc.

Key questions are answered in this report.

  • Which pharmaceutical companies are manufacturing intravitreal injectables for treating eye disorders?
  • What are the strengths, weaknesses, and opportunities associated with the growth of the intravitreal injectables market?
  • What is the pathophysiology associated with diseases such as macular degeneration, diabetic retinopathy, and endophthalmitis?
  • Which treatment regimen is considered for the treatment of macular degeneration?
  • What is the pharmacodynamic effect of anti-VEGF drugs in treating eye disorders?
  • What will be the market assessment for intravitreal injectables in the Asia-Pacific regional market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global II Market Portraiture
2.2. Global II Market, by Indication, 2017 (US$ Mn)
2.3. Global II Market, by Drug Class, 2017 (US$ Mn)
2.4. Global II Market, by Geography, 2017 (US$ Mn)

Chapter 3. Intravitreal Injectables (II) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global II Market, by Key Players, 2017

Chapter 4. Global Intravitreal Injectables (II) Market, by Indication
4.1. Overview
4.2. Macular Degeneration
4.3. Diabetic Retinopathy
4.4. Retinal Vein Occlusions
4.5. Endophthalmitis
4.6. Others

Chapter 5. Global Intravitreal Injectables (II) Market, by Drug Class
5.1. Overview
5.2. Anti-VEGF
5.3. Corticosteroids
5.4. Antibiotics
5.5. Antivirals
5.6. Antifungals

Chapter 6. Global Intravitreal Injectables (II) Market, by Geography
6.1. Overview
6.2. North America II Market Analysis, 2016 – 2026
6.2.1. North America II Market, by Indication, 2016 – 2026 (US$ Mn)
6.2.2. North America II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.2.3. North America II Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe II Market Analysis, 2016 – 2026
6.3.1. Europe II Market, by Indication, 2016 – 2026 (US$ Mn)
6.3.2. Europe II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.3.3. Europe II Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific II Market Analysis, 2016 – 2026
6.4.1. Asia Pacific II Market, by Indication, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific II Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America II Market Analysis, 2016 – 2026
6.5.1. Latin America II Market, by Indication, 2016 – 2026 (US$ Mn)
6.5.2. Latin America II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.5.3. Latin America II Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa II Market Analysis, 2016 – 2026
6.6.1. MEA II Market, by Indication, 2016 – 2026 (US$ Mn)
6.6.2. MEA II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.6.3. MEA II Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Allergan, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Alimera Sciences
7.3. Bristol-Myers Squibb Company
7.4. Eyetech, Inc.
7.5. F. Hoffmann-La Roche Ltd
7.6. Genentech, Inc.
7.7. Novartis AG
7.8. Regeneron Pharmaceuticals, Inc.
7.9. ThromboGenics, Inc.
7.10. Valeant Pharmaceuticals International, Inc.

List of Figures

FIG. 1 : Intravitreal Injectables (II) Market: Research Methodology
FIG. 2 : II: Market Segmentation
FIG. 3 : Global II Market, by Indication, 2017 (US$ Mn)
FIG. 4 : Global II Market, by Drug Class, 2017 (US$ Mn)
FIG. 5 : Global II Market, by Geography, 2017 (US$ Mn)
FIG. 6 : Attractive Investment Proposition: by Geography, 2017
FIG. 7 : Competitive Analysis: Global II Market, by Key Players, 2017
FIG. 8 : Global Macular Degeneration Market for II, 2016 – 2026 (US$ Mn)
FIG. 9 : Global Diabetic Retinopathy Market for II, 2016 – 2026 (US$ Mn)
FIG. 10 : Global Retinal Vein Occlusions Market for II, 2016 – 2026 (US$ Mn)
FIG. 11 : Global Endophthalmitis Market for II, 2016 – 2026 (US$ Mn)
FIG. 12 : Global Other Indications Market for II, 2016 – 2026 (US$ Mn)
FIG. 13 : Global Anti-VEGF Market for II, 2016 – 2026 (US$ Mn)
FIG. 14 : Global Corticosteroids Market for II, 2016 – 2026 (US$ Mn)
FIG. 15 : Global Antibiotics Market for II, 2016 – 2026 (US$ Mn)
FIG. 16 : Global Antivirals Market for II, 2016 – 2026 (US$ Mn)
FIG. 17 : Global Antifungals Market for II, 2016 – 2026 (US$ Mn)
FIG. 18 : U.S. II Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Canada II Market, 2016 – 2026 (US$ Mn)
FIG. 20 : U.K. II Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Germany II Market, 2016 – 2026 (US$ Mn)
FIG. 22 : Rest of Europe II Market, 2016 – 2026 (US$ Mn)
FIG. 23 : China II Market, 2016 – 2026 (US$ Mn)
FIG. 24 : Japan II Market, 2016 – 2026 (US$ Mn)
FIG. 25 : Rest of Asia Pacific II Market, 2016 – 2026 (US$ Mn)
FIG. 26 : Brazil II Market, 2016 – 2026 (US$ Mn)
FIG. 27 : Mexico II Market, 2016 – 2026 (US$ Mn)
FIG. 28 : Rest of Latin America II Market, 2016 – 2026 (US$ Mn)
FIG. 29 : GCC II Market, 2016 – 2026 (US$ Mn)
FIG. 30 : Rest of MEA II Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 : Global Intravitreal Injectables (II) Market Portraiture
TABLE 2 : Global II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 3 : Global II Market , by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 4 : Global II Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 : North America II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 6 : North America II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 : North America II Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 : Europe II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 9 : Europe II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 10 : Europe II Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 : Asia Pacific II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 12 : Asia Pacific II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 13 : Asia Pacific II Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 : Latin America II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 15 : Latin America II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 16 : Latin America II Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 : Middle East and Africa II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 18 : Middle East and Africa II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 19 : Middle East and Africa II Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 : Allergan, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 : Alimera Sciences: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 : Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 : Eyetech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 : F.Hoffman-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 : Genetech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 : Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 : Regeneron Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 : ThromboGenics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 : Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions:

What is the size of Intravitreal Injectables Market?

The market for Intravitreal Injectables Market is expected to reach At XX Mn in 2026.

What is the Intravitreal Injectables Market CAGR?

The Intravitreal Injectables Market is expected to see significant CAGR growth over the coming years, at 4.8%.

What is the Forecast period considered for Intravitreal Injectables Market?

The report is forecasted to 2018-2026

What is the base year considered for Intravitreal Injectables Market?

The base year of this report is 2017.

Who are the major players in this market?

Allergan, Inc., Alimera Sciences,Bristol-Myers Squibb Company,Eyetech Inc.,F.Hoffmann-La Roche Ltd. are some of the major players in the global market.

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Basal Cell Carcinoma (BCC) Treatment Market

Published:
Report ID: 32698

Paroxysmal Nocturnal Hemoglobinuria Market

Published:
Report ID: 8654

Reversible Airway Diseases Treatment Market

Published:
Report ID: 32531

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN